U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H24O2.C2H6NO3S.Na
Molecular Weight 347.446
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM TAURINE LAURATE

SMILES

[Na+].NCCS([O-])(=O)=O.CCCCCCCCCCCC(O)=O

InChI

InChIKey=HLGSTHXLGGPEDB-UHFFFAOYSA-M
InChI=1S/C12H24O2.C2H7NO3S.Na/c1-2-3-4-5-6-7-8-9-10-11-12(13)14;3-1-2-7(4,5)6;/h2-11H2,1H3,(H,13,14);1-3H2,(H,4,5,6);/q;;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H24O2
Molecular Weight 200.3178
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H6NO3S
Molecular Weight 124.139
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 | https://www.ncbi.nlm.nih.gov/pubmed/26208967

Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.

Originator

Curator's Comment: Taurin was first isolated from ox bile in 1827.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
406.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAURINE

Approved Use

Taking 2-3 grams of taurine by mouth one to two times daily for 6-8 weeks seems to improve heart function and symptoms in patients with moderate heart failure to severe heart failure. Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year.
Palliative
TAURINE

Approved Use

Taking 1.5-4 grams of taurine daily for up to 3 months improves liver function in people with hepatitis.
Preventing
URSA Complex

Approved Use

Taurine is a component of energy drinks used for relieving of fatigue
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Amino acids as biochemical markers in epidemic and endemic optic neuropathies].
1998
Bile acid synthesis in cultured human hepatocytes: support for an alternative biosynthetic pathway to cholic acid.
2000 Jun
Calcium-mediated transductive systems and functionally active gap junctions in astrocyte-like GL15 cells.
2001
Changes in plasma and urinary taurine and amino acids in runners immediately and 24h after a marathon.
2001
Gene expression of the taurine transporter and taurine biosynthetic enzymes in rat kidney after antidiuresis and salt loading.
2001 Apr
Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection.
2001 Apr 13
Effects of new taurine derivatives on primary immune response in rats.
2001 Feb
Aging-induced changes in 24-h rhythms of mitogenic responses, lymphocyte subset populations and neurotransmitter and amino acid content in rat submaxillary lymph nodes during Freund's adjuvant arthritis.
2001 Feb
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy.
2001 Feb
Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels.
2001 Feb
[Effect of taurine on the microvessel exchange function and adrenergic response of veins and arteries in the cat skeletal muscle].
2001 Jan
MR diffusion imaging and 1H spectroscopy in a child with medulloblastoma. A case report.
2001 Jan
Studies on the effects of lactate transport inhibition, pyruvate, glucose and glutamine on amino acid, lactate and glucose release from the ischemic rat cerebral cortex.
2001 Jan
Nucleoside transport inhibition in ischemic myocardium results in enhanced taurine efflux.
2001 Jan 5
Neurotoxic effect of acamprosate, n-acetyl-homotaurine, in cultured neurons.
2001 Jan-Feb
Taurine modulates catalase, aldehyde dehydrogenase, and ethanol elimination rates in rat brain.
2001 Jan-Feb
Taurine modulates arginine vasopressin-mediated regulation of renal function.
2001 Jun
Effects of acamprosate on ethanol-seeking and self-administration in the rat.
2001 Mar
Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters.
2001 Mar
Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine.
2001 Mar
Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers.
2001 May
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
2001 May
The influence of plasma on the disinfecting activity of the new antimicrobial agent N-chlorotaurine-sodium in comparison with chloramine T.
2001 May
N-chlorotaurine, a novel endogenous antimicrobial agent: tolerability testing in a mouse model.
2001 May
High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1.
2001 May
Patents

Sample Use Guides

Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg.
Route of Administration: Oral
In Vitro Use Guide
Agonist properties of taurine on glycine receptor of supraoptic magnocellular neurones acutely dissociated from adult rats, using whole-cell voltage clamp. Responses to 1 mM taurine were blocked by strychnine but not by gabazine and showed no additivity with glycine-induced currents, indicating selective activation of glycine receptors.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:43:13 UTC 2023
Edited
by admin
on Sat Dec 16 01:43:13 UTC 2023
Record UNII
ZYS0US400F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM TAURINE LAURATE
INCI  
INCI  
Official Name English
DODECANOIC ACID, COMPD. WITH 2-AMINOETHANESULFONIC ACID MONOSODIUM SALT (1:1)
Common Name English
ETHANESULFONIC ACID, 2-AMINO-, COMPD. WITH DODECANOIC ACID, SODIUM SALT (1:1:1)
Common Name English
SODIUM TAURINE LAURATE [INCI]
Common Name English
DODECANOIC ACID, 2-AMINOETHANESULFONIC, SODIUM SALT
Common Name English
ETHANESULFONIC ACID, 2-AMINO-, MONOSODIUM SALT, DODECANOATE
Common Name English
Code System Code Type Description
FDA UNII
ZYS0US400F
Created by admin on Sat Dec 16 01:43:13 UTC 2023 , Edited by admin on Sat Dec 16 01:43:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID00172872
Created by admin on Sat Dec 16 01:43:13 UTC 2023 , Edited by admin on Sat Dec 16 01:43:13 UTC 2023
PRIMARY
RXCUI
2399553
Created by admin on Sat Dec 16 01:43:13 UTC 2023 , Edited by admin on Sat Dec 16 01:43:13 UTC 2023
PRIMARY
CAS
192750-09-7
Created by admin on Sat Dec 16 01:43:13 UTC 2023 , Edited by admin on Sat Dec 16 01:43:13 UTC 2023
PRIMARY
PUBCHEM
23668864
Created by admin on Sat Dec 16 01:43:13 UTC 2023 , Edited by admin on Sat Dec 16 01:43:13 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY